JNJ vs VKTX

Johnson & Johnson (JNJ) continues to demonstrate robust financial performance, with Q1 2026 results exceeding consensus on both revenue and adjusted EPS, reflecting nearly 10% YoY revenue growth. Its diversified healthcare portfolio provides significant market leadership and a wide economic moat, indicating stability and consistent profitability. However, its massive market capitalization of $555....

Viking Therapeutics maintains strong 10x growth potential, with its lead asset VK2735 (a dual GLP-1/GIP agonist) continuing to show compelling clinical promise in the lucrative metabolic disorder market. Recent additional positive Phase 2 data for the oral formulation, showing up to 12.2% weight loss, reinforces its potential as a best-in-class option and strengthens its competitive position. Whil...